Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Sanofi-Aventis Licenses Anti-Angiogenesis Technology from SIBS

publication date: Dec 6, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sanofi-Aventis has in-licensed a technology patent from Shanghai Institutes for Biological Sciences (SIBS) that may lead to an anti-angiogenesis cancer drug. The patent covers SIBS’s discovery of the importance of the Slit-Robo signaling path for tumor vasculature and tumor growth. The total deal is worth $60 million, according to Data Monitor, which includes an upfront payment, milestones and royalties on sales. More details....

Stock Symbol: (NYSE: SNY)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...